Changing the course of cancer treatment

We explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.

Mendus Publishes Annual Report 2025

Read the annual report

Mendus presents data on vididencel in high-risk ovarian cancer

Read More

Mendus publishes financial report for Q1 2026

More details

First Patient Enrolled in the VITAL-CML Trial

Read More

Mendus Publishes Annual Report 2025

Read the annual report

Mendus presents data on vididencel in high-risk ovarian cancer

Read More

Latest news

No articles found